United Therapeutics Corporation (UTHR) Q4 FY25 Earnings Call

Record growth and multiple planned launches support upside, but key clinical and regulatory milestones remain unresolved.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-25
Length34 minutes
EPS$7.70
EPS consensus$6.78
Revenue$790.2M
Revenue consensus$814.8M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26 · Q2 FY25

All UTHR earnings · Back to UTHR overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.